- Home
- CSAN vs CORT Comparison
CSAN vs CORT Comparison
Compare CSAN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSAN | CORT |
|---|---|---|
| Founded | 1936 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2008 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CSAN | CORT |
|---|---|---|
| Price | $2.89 | $83.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.75 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.7M | 984.7K |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $321.51 | $26.08 |
| Revenue Next Year | $3.57 | $26.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $2.52 | $28.66 |
| 52 Week High | $6.01 | $91.00 |
Technical Indicators
Market Signals| Indicator | CSAN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 78.89 |
| Support Level | $2.52 | $68.49 |
| Resistance Level | $4.37 | $90.00 |
| Average True Range (ATR) | 0.12 | 3.75 |
| MACD | 0.07 | -0.44 |
| Stochastic Oscillator | 98.81 | 99.38 |
Price Performance
Historical ComparisonAbout CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.